Kaplan Fox Has Filed a Class Action to Recover Losses for Investors Who Purchased Boston Scientific Corporation Securities
News provided by
Share this article
Share this article
NEW YORK, Jan. 6, 2021 /PRNewswire/ Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has filed a class action suit in the United States District Court for the District of Massachusetts against Boston Scientific Corporation ( Boston Scientific or BSX or the Company ) (NYSE: BSX) and certain of its executives.
The Complaint alleges that Defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission, and is brought by plaintiff on behalf of all persons and entities who purchased the publicly traded securities of Boston Scientific during the period April 24, 2019 through November 16, 2020, inclusive ( Class Period ).
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Kaplan Fox Files Class Action to Recover Losses for Investors Who Purchased Boston Scientific .
Kaplan Fox & Kilsheimer LLPDecember 16, 2020 GMT
NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) Kaplan Fox & Kilsheimer LLP ( www.kaplanfox.com ) has filed a class action suit in the United States District Court for the District of Massachusetts against Boston Scientific Corporation (“Boston Scientific” or “BSX” or the “Company”) (NYSE: BSX) and certain of its executives.
The Complaint alleges that Defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission, and is brought by plaintiff on behalf of all persons and entities who purchased the publicly traded securities of Boston Scientific during the period April 24, 2019 through November 16, 2020, inclusive (“Class Period”
Share this article
Share this article
NEW YORK, Dec. 16, 2020 /PRNewswire/ Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of FireEye, Inc. ( FireEye or the Company ) (NASDAQ: FEYE).
On December 8, 2020, after the market closed, cybersecurity company FireEye disclosed in a Form 8-K filing with the SEC that the Company was attacked by a highly sophisticated cyber threat actor and that it was investigating the incident in coordination with the Federal Bureau of Investigation and other key partners.
Following this news, FireEye s shares fell $2.03 per share, more than 13%, to close at $13.49 per share on December 9, 2020.
Share this article
Share this article
NEW YORK, Dec. 16, 2020 /PRNewswire/ Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of SolarWinds Corporation ( SolarWinds or the Company ) (NYSE: SWI), a software company that provides IT management tools.
On December 8, 2020, cybersecurity company FireEye, Inc. ( FireEye ) announced that FireEye was attacked by a highly sophisticated cyber threat actor and investigating the incident with the FBI and other key partners. Later, on Sunday, December 13, 2020, FireEye provided an update that the compromise is delivered through updates to a widely-used IT infrastructure management software –
the Orion network monitoring product from SolarWinds.
Share this article
Share this article
NEW YORK, Dec. 17, 2020 /PRNewswire/ Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Penumbra, Inc ( Penumbra or the Company ) (NYSE: PEN).
On Nov. 9, 2020, Quintessential Capital Management ( QCM ) published a report entitled Penumbra and its Killer Catheter. QCM stated, among other things that Penumbra s flagship Jet 7 device is linked to 18 recorded deaths, 39 injuries and that this might be only the tip of the iceberg. . . .
On November 9, 2020, Penumbra s shares fell $8.76 per share, about 3.5%, to close at $242.46 per share.
On December 8, 2020, QCM published another report accusing Penumbra of having engaged in a multi-year scheme to fraudulently produce a substantial portion of scientific literature using a fake character to support its product marketing to healthcare providers.